Latest News

New York, New York--(Newsfile Corp. - August 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cogent Communications Holdings, Inc. (NASDAQ: CCO

Goldman Sachs ETF acquisitions and the blurring line between investing and gambling headlined this week's ETF Prime. Host Nate Geraci welcomed Mike Akins, founding partner at ETF Action, followed by P

Abnormal AI will expand its use of OpenAI to support its Behavioral AI products that stop cybersecurity attacks, Abnormal AI said in a Wednesday (Aug. 19) press release. Abnormal's solutions protect m

Merck & Co., Inc. surges to all-time highs after positive Phase 3 melanoma vaccine trial results with Moderna. MRK maintains a Buy rating, citing strong oncology growth, robust free cash flow, and tec

New York, New York--(Newsfile Corp. - August 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alarum Technologies Ltd. (NASDAQ: ALAR) between Mar

New York, New York--(Newsfile Corp. - August 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc.

Okta TodayOKTAOkta$142.63 -1.29 (-0.89%) As of 12:11 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$62.66▼$157.00P/E Ratio103.50Price Target$134.11Add to Wa

Franklin Intl Low Volatility High Dividend Index ETF (LVHI) remains a buy, now primarily for its currency protection amid potential future interest rate hikes. LVHI's hedged strategy shields dividends

Moderna and Merck jump on positive results for melanoma cure. Federal Open Market Committee notes become public this afternoon.

Cinemark on Tuesday became the latest major theater operator to toss its hat in the ring, after AMC Theatres and Regal Cinemas previously backed the $110 billion Paramount-Warner Bros. Discovery merge

Meta Platforms, Inc. stock is under pressure amid renewed AI bubble fears, and legal headwinds, yet the fundamental thesis is not broken, presenting a compelling risk-reward opportunity. META's aggres

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Intuit To Contact Him Directly To Discuss Their Options If you purchased or acquired

IBM (IBM) achieved a milestone by linking and cooling two cryogenic modules, advancing toward a fault-tolerant quantum computer. Target (TGT) delivered strong Q2 results, exceeding expectations on EPS

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In EquipmentShare To Contact Him Directly To Discuss Their Options If you purchased or a

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hub Group To Contact Him Directly To Discuss Their Options If you purchased or acquir

New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Avis Budget Group, Inc. ("Avis" or the "Company") (NAS

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Megan To Contact Him Directly To Discuss Their Options If you purchased or acquired s

ATI delivered strong, upbeat Q2 FY26 results with an over 10.6% increase in its revenue and strong margin expansion, underscoring ATI's progress and recovery in certain parts of the business. Strong b

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options If you purchased or acquir

BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones. Alesta Therapeutic's lead drug is a potential treatment for hypophosphatas